J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0091270006299136v1
47/5/628    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krishna, G.
Right arrow Articles by Wang, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krishna, G.
Right arrow Articles by Wang, Z.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

PHARMACOKINETICS

The Effect of Omeprazole on the Bioavailability and Safety of Garenoxacin in Healthy Volunteers

Gopal Krishna, PhD, James C. Kisicki, MD, Steven Olsen, MS, Dennis M. Grasela, PharmD, PhD and Zaiqi Wang, MD, PhD

From the Department of Pharmacokinetics and Department of Early Clinical Research & Experimental Medicine, Schering-Plough Research Institute, Kenilworth, New Jersey (Dr Krishna, Dr Wang); MDS Pharma Services, Lincoln, Nebraska (Dr Kisicki); and Bristol-Myers Squibb Co, Princeton, New Jersey (Mr Olsen, Dr Grasela).

The effect of coadministration of omeprazole on the bioavailability of oral garenoxacin was evaluated in an open-label study in 14 healthy subjects. Single-dose pharmacokinetics of garenoxacin were determined with and without steady-state omeprazole. Following an oral dose of garenoxacin 600 mg on day 1, serial blood samples were obtained over the next 72 hours. Omeprazole 40 mg once daily was administered from days 4 to 10. A second pharmacokinetic assessment of garenoxacin was conducted on day 8. Geometric means for the maximum observed concentration and area under the concentration-time curve from time 0 extrapolated to infinity were 9.6 µg/mL (18.2%) and 132.0 µg·h/mL (18.9%), respectively, for garenoxacin alone and 9.3 µg/mL (21.6%) and 140.4 µg·h/mL (22.1%), respectively, for coadministered garenoxacin and omeprazole. The 90% confidence interval for the ratio of geometric means (with/without omeprazole) for both variables was contained within 0.80 to 1.25, and the bioavailability of garenoxacin was not affected by the concomitant administration of omeprazole.

Key Words: Bioavailability • drug interaction • garenoxacin • omeprazole • pharmacokinetics • quinolone

Address for reprints: Address for correspondence: Gopal Krishna, PhD, Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033; e-mail: Gopal.Krishna{at}spcorp.com.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American College of Clinical Pharmacology